About
Neurophyxia is a clinical-stage drug development company developing neuroprotective drugs to reduce damage from oxygen shortage in the brain. Its lead product, 2-IB, is in Phase IIb/III clinical development for stroke, with additional indications including birth asphyxia and cardiac arrest.
Explore Neurophyxia's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.